What is US Patent 8609647 for Delgocitinib?
U.S. Patent 8,609,647 is a key patent covering delgocitinib, an orally administered Janus kinase (JAK) inhibitor developed for treating inflammatory skin diseases such as atopic dermatitis [1]. This patent, assigned to AnaptysBio, Inc., protects the composition of matter for delgocitinib, specifically its chemical compound [2].
When Does the Patent for Delgocitinib Expire?
The listed expiration date for U.S. Patent 8,609,647 is August 25, 2026 [3]. This date marks the end of the patent's protection period, after which generic versions of delgocitinib could potentially be manufactured and sold, assuming all regulatory approvals are met [4].
What is Delgocitinib's Mechanism of Action?
Delgocitinib is designed to inhibit JAK enzymes. These enzymes play a crucial role in signaling pathways that mediate inflammation and immune responses [1]. By blocking JAK activity, delgocitinib aims to reduce the inflammation associated with conditions like atopic dermatitis [1].
How is Delgocitinib Being Studied for Atopic Dermatitis?
Delgocitinib has been investigated in clinical trials for its efficacy and safety in treating atopic dermatitis. These studies aim to demonstrate its potential as a treatment option for moderate-to-severe cases of the condition [1].
Who Developed Delgocitinib?
AnaptysBio, Inc. is the company associated with the development of delgocitinib [2]. They hold the U.S. patent for the compound [2].
What are the Potential Risks and Side Effects of Delgocitinib?
As with any medication, delgocitinib carries potential risks and side effects. The specific adverse events associated with delgocitinib would be detailed in its prescribing information and observed during clinical trials [1]. JAK inhibitors as a class can have associated risks, which are carefully monitored during drug development and post-market surveillance [1].
How Does Delgocitinib Compare to Other Atopic Dermatitis Treatments?
Delgocitinib belongs to a class of medications that target specific inflammatory pathways. Its efficacy and safety profile are evaluated against existing treatments for atopic dermatitis, including topical corticosteroids, calcineurin inhibitors, and other systemic agents [1]. The development of new oral JAK inhibitors like delgocitinib offers alternative therapeutic options for patients who may not respond well to or tolerate current therapies [1].
What is the Status of Delgocitinib's Regulatory Approval?
Information regarding the current regulatory status of delgocitinib, including any approvals or pending applications, would be available through regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1].
Where Can I Find More Information on Drug Patents?
DrugPatentWatch.com provides a comprehensive database of drug patents, expiration dates, and related information [5].
*
**Sources:
1. https://www.drugpatentwatch.com/drug/delgocitinib
2. https://patents.google.com/patent/US8609647B2/en
3. https://www.drugpatentwatch.com/us-patent/8609647
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/